Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 s Revenues Down, Losses Up in Q3; Company to Sell Software Business

NEW YORK, June 15 (GenomeWeb News) - Accelr8 Technology today reported dwindling revenues and increased losses for the third quarter of its fiscal year 2004, which ended April 30.


The company had $132,000 in revenues for the quarter, down from $276,000 during the same quarter last year.


R&D costs remained flat at $128,000, compared to $122,000 during the year-ago quarter.


Accelr8 recorded a net loss of $335,000, or $.03 per share, up from $214,000, or $.02 per share, during the third quarter last year.


Last month, the company said it will sell its software business by the end of July, allowing it "to devote its full attention to advancing the biosciences side" of its business, according to a company statement. Accelr8 values the sale at $700,000, including $200,000 in deferred maintenance revenue.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.